… The Dapagliflozin and Prevention of Adverse outcomes in CKD (DAPA-CKD) trial tested
the hypothesis that compared with placebo, the SGLT2 inhibitor dapagliflozin is superior in …

… We evaluated the efficacy and safety of dapagliflozin, which … SBP in Dapagliflozin and
Prevention of Adverse Outcomes in … of dapagliflozin compared with placebo on each outcome was …

… Efficacy outcomes The primary outcome for the evaluation of the effect of dapagliflozin on
delaying the progression of renal disease is the time to the first occurrence of any of the …

Background The aims of this study were to: (i) report the baseline characteristics of patients
enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐…

… of the primary composite outcome with dapagliflozin in patients … of dapagliflozin and placebo
for the primary outcome in … the fields of hypertension and preventive Cardiology (with the ‘…

… Adverse events leading to study drug discontinuation were similar in both groups; there were
fewer serious adverse events with dapagliflozin… serious adverse events with dapagliflozin …

… of dapagliflozin on abrupt declines in kidney function. These events were captured in the
DAPA-CKD trial as a pre-specified exploratory outcome, … of serious AKI adverse events (as …

… and serious adverse events were not more frequent in the dapagliflozin group than in the …
effects of dapagliflozin vs placebo on the primary outcome and secondary clinical outcomes in …

… disease (CKD) and the possibility of using dapagliflozin at a dose of 10 mg once a day …
with dapagliflozin and in 14.5% of patients treated with placebo. Also, dapagliflozin therapy was …

… adverse effects of long-term dapagliflozin therapy related to the mechanism of action of SGLT2
inhibitors, including adverse … benefits of dapagliflozin in the prevention and treatment of …